Cefiderocol is Not Sequestered in an Ex Vivo Extracorporeal Membrane Oxygenation (ECMO) Circuit

被引:6
作者
Berry, Angela V. [1 ]
Conelius, Allison [2 ]
Gluck, Jason A. [2 ]
Nicolau, David P. [1 ]
Kuti, Joseph L. [1 ]
机构
[1] Hartford Hosp, Ctr Antiinfect Res & Dev, 80 Seymour St, Hartford, CT 06102 USA
[2] Hartford Hosp, Heart & Vasc Inst, Hartford, CT USA
关键词
DRUGS;
D O I
10.1007/s13318-023-00840-w
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Background and ObjectiveExtracorporeal membrane oxygenation (ECMO) is used in critically ill patients that require respiratory and/or cardiac support. Cefiderocol is a novel siderophore antibiotic that may require use in infected critically ill patients supported by ECMO. The objective of this study was to determine the loss of cefiderocol through an ex vivo adult ECMO circuit using a Quadrox-iD oxygenator.MethodsA 3/8-inch, simulated, ex vivo closed-loop ECMO circuit was prepared with a Quadrox-iD adult oxygenator and primed with fresh whole blood. Cefiderocol was administered into the circuit to achieve a starting concentration of approximately 90 mg/L. Post-oxygenator blood samples were collected at 0, 0.25, 0.5, 1, 2, 4, 6, 12, and 24 h after the addition of the drug to determine the loss in the circuit. A glass control jar was prepared with the same blood matrix and maintained at the same temperature to determine drug degradation. The experiment was conducted in triplicate. The rate of cefiderocol loss in the ECMO circuit was compared with that in the control by one-way analysis of variance.ResultsAt 0 h, the difference between the pre- and post-oxygenator concentrations was - 4 & PLUSMN; 4% (range 0 to - 7%). After 24 h, the cefiderocol percent reduction was similar between the ECMO circuit and control (50% & PLUSMN; 13 vs. 50% & PLUSMN; 9, p = 1.0).ConclusionsThe degradation rate of cefiderocol did not differ significantly within the ECMO circuit and control, suggesting no loss due to sequestration or adsorption. Pharmacokinetic studies in patients supported by ECMO are warranted to determine final dosing recommendations.
引用
收藏
页码:437 / 441
页数:5
相关论文
共 15 条
  • [11] Pharmacokinetics and Dosing of Anti-infective Drugs in Patients on Extracorporeal Membrane Oxygenation: A Review of the Current Literature
    Sherwin, Jennifer
    Heath, Travis
    Watt, Kevin
    [J]. CLINICAL THERAPEUTICS, 2016, 38 (09) : 1976 - 1994
  • [12] Shionogi Inc, 2020, CEF FETR PACK INS
  • [13] SHOULD WE FEAR TUBING ADSORPTION OF ANTIBACTERIAL DRUGS IN EXTRACORPOREAL MEMBRANE OXYGENATION? AN ANSWER FOR CEPHALOSPORINS AND CARBAPENEMS
    Tron, Camille
    Leven, Cyril
    Fillatre, Pierre
    Maillard, Nicolas
    Nesseler, Nicolas
    Tattevin, Pierre
    Flecher, Erwan
    Bellissant, Eric
    Verdier, Marie-Clemence
    Lemaitre, Florian
    [J]. CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY, 2016, 43 (02) : 281 - 283
  • [14] HMDB 4.0: the human metabolome database for 2018
    Wishart, David S.
    Feunang, Yannick Djoumbou
    Marcu, Ana
    Guo, An Chi
    Liang, Kevin
    Vazquez-Fresno, Rosa
    Sajed, Tanvir
    Johnson, Daniel
    Li, Carin
    Karu, Naama
    Sayeeda, Zinat
    Lo, Elvis
    Assempour, Nazanin
    Berjanskii, Mark
    Singhal, Sandeep
    Arndt, David
    Liang, Yonjie
    Badran, Hasan
    Grant, Jason
    Serra-Cayuela, Arnau
    Liu, Yifeng
    Mandal, Rupa
    Neveu, Vanessa
    Pon, Allison
    Knox, Craig
    Wilson, Michael
    Manach, Claudine
    Scalbert, Augustin
    [J]. NUCLEIC ACIDS RESEARCH, 2018, 46 (D1) : D608 - D617
  • [15] Cefiderocol: A Novel Agent for the Management of Multidrug-Resistant Gram-Negative Organisms
    Wu, Janet Y.
    Srinivas, Pavithra
    Pogue, Jason M.
    [J]. INFECTIOUS DISEASES AND THERAPY, 2020, 9 (01) : 17 - 40